Related Experiment Videos
[Antihypertensive treatment and left ventricular hypertrophy]
E Agabiti-Rosei1, M L Muiesan, D Rizzoni
1Cattedra di Semeiotica e Metodologia Medica, Università degli Studi di Brescia.
Insights
Left ventricular hypertrophy (LVH) in hypertension can lead to heart failure. Certain antihypertensive drugs, like ACE inhibitors, are more effective in reducing LVH, potentially improving heart function.
Area of Science:
- Cardiology
- Hypertension Research
- Cardiac Physiology
Context:
- Left ventricular hypertrophy (LVH) is an adaptive response to increased afterload in arterial hypertension.
- LVH is an independent risk factor for cardiovascular morbidity and mortality.
- Reversing LVH is a critical therapeutic goal for hypertensive patients.
Purpose:
- To evaluate the impact of different antihypertensive drug classes on left ventricular mass.
- To determine if pharmacological interventions beyond blood pressure control can reduce cardiac hypertrophy.
- To assess the functional consequences of LVH reversal.
Summary:
- Different antihypertensive drugs vary in their efficacy for reducing left ventricular mass.
- ACE inhibitors, calcium antagonists, and sympathetic nervous system modulators show superior effects in decreasing LVH.
- Reversal of cardiac hypertrophy correlates with improved functional outcomes.
Impact:
- Identifies specific antihypertensive drug classes most effective for LVH regression.
- Highlights the importance of targeting mechanisms beyond blood pressure control for cardiac remodeling.
- Suggests potential for improved cardiovascular outcomes through LVH reversal, warranting further survival studies.
Abstract:
Left ventricular hypertrophy in arterial hypertension can be considered as an adaptive response of the heart to the increased afterload, in order to reduce wall stress; however, cardiac hypertrophy can also represent the first step toward a pathological process that leads to the development of congestive heart failure. Epidemiological studies have documented that left ventricular hypertrophy in essential hypertension represents an independent risk factor for cardiovascular morbidity and mortality. The possibility of reversing, or even preventing, left ventricular hypertrophy through a reduction in elevated blood pressure values and modification of some other pathogenetic factors should represent a major therapeutic need in the treatment of hypertensive patients. It has been demonstrated that different classes of antihypertensive drugs do not have the same effect in reducing left ventricular mass, probably because beyond control of blood pressure, the pharmacological interference with adrenergic system, the renin-angiotensin-aldosterone system or other growth factors can influence the development and the reduction of cardiac hypertrophy. Two recent meta-analyses of the principal regression studies have shown that ACE-inhibitors, followed by calcium antagonists and drugs capable of reducing sympathetic nervous system activity, are more effective in decreasing left ventricular mass. The results of experimental and clinical studies have demonstrated that the reversal of cardiac hypertrophy is associated with an improvement of the functional consequences of an increased left ventricular mass. Further studies are needed in order to verify whether the reversal of left ventricular hypertrophy per se increases survival in essential hypertensive patients.